I
I listened to the video again. And I am wondering, how would one unblock a circuit? Dr Davis says that there are many drugs out there. How would unblocking work?
This is far too general a question to have a good answer. The reply is going to be some version of "it depends", or so general its almost meaningless. In biochemical blocks there will be some failure in an enzyme or transporter, or some failure in regulation, which typically means a failure in an enzyme or transporter. Now in a trap situation there will be multiple effects driving each other.
All these effects might have to be identified. Then you treat each one, at the same time. For an enzyme you might use an activator or deactivator drug, or a drug targeting an activating or deactivating process. You might also supply additional enzyme cofactors, often a B vitamin. A transporter is trickier, and it depends on why and how the transporter is defective. However I think a lot of the time the story will be similar to that of an enzyme.
By a circuit I think Ron means either a circular causal pathway, or a specific molecular switch that is basically on or off, though its probably more like a dimmer switch. How that switch works will give you clues on how to treat it. The big risk occurs if its less a feedback or feedforward loop than its a spaghetti tangle of loops. Those might be hard to figure out, and require a lot of research.
I think it much more likely to be some kinds of feefback loops, rather than feedforward, as I would expect to see rapidly progressing pathology as a risk in feedforward loops. ME pathology seems to mostly be about have a set state, and that implies some kind of feedback effect.
The way existing drugs would be initially tested might be like this. Using the nanoneedle test that identifies a probable problem in ME cells, you create a testbed. Many samples on a tray, many nanoneedles. Then for each column or row you add a specific drug, probably at a high dose initially. If you see an improvement it can then go to the next phase of testing. If not you move to the next drug. Thousands of drugs might be tested this way rather quickly, giving us a short list of possible drugs.
Further testing of candidate drugs might however take more time, effort and resources. Eventually some form of clinical trials might be necessary, though for already approved drugs they could be used off label before such trials are completed.
Its only when we have more science published that we can begin to really look at this.